Navigation Links
Pharmaburst(R) 500: Optimized, Evolutionary ODT Performance
Date:8/11/2009

WILMINGTON, Del., Aug. 11 /PRNewswire/ -- SPI Pharma, Inc., a leader in oral dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) platforms, recently announced the launch of Pharmaburst(R) 500. Using proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly raise the bar in terms of performance and economics that formulators have come to expect from a quick-dissolve dosage form.

Studies show that Pharmaburst(R) 500 outperforms all of its direct competitors with respect to product functionality and organoleptics. It is easy to use, cost-effective and readily formulated with various actives to make robust orally disintegrating tablets (ODTs). The finished ODT can be manufactured internally rather than through outsourcing.

Pharmaburst(R) was the first off-the-shelf, patented, co-processed ODT excipient system introduced in the pharmaceutical market. It is still the only ODT excipient system included in the US FDA's Inactive Ingredient Guide (IIG). It is now being used in a wide variety of new and generic drug applications around the world by many leading multinationals and several top generic companies.

Oral dispersible drugs containing Pharmaburst(R) have been successfully launched in regulated and developing markets around the world for indications such as migraine, allergy, analgesics, anxiety, oncology, schizophrenia, depression, and Parkinson's.

For more information, please visit www.spipharma.com.


'/>"/>
SOURCE SPI Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
2. ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384
3. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)
4. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
5. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
6. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
7. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
8. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
9. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
10. Worlds Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc.
11. Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):